LAPTM4B and non-small cell lung carcinoma: Moreover, our data also identified that OS and PFS of LAC patients were significantly worse in the LAPTM4B high expression group compared to the low expression group and the result was consistent with the previous study reporting that LAPTM4B was associated with poor survival in LAC but not in all NSCLC patients [17].